Trials / Completed
CompletedNCT00871936
A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of SLx-4090 in Combination With Metformin in Subjects With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 82 (actual)
- Sponsor
- Response Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether SLx-4090 in combination with metformin therapy will reduce HbA1c in patients with Type 2 Diabetes more effectively than metformin therapy alone.
Detailed description
1. HbA1c after 12 weeks 2. FPG after 12 weeks 3. Safety and tolerability 4. Plasma levels of SLx-4090
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SLx-4090 | SLx-4090 |
| OTHER | Placebo | matching tablets |
| DRUG | Metformin |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2009-10-01
- Completion
- 2009-10-01
- First posted
- 2009-03-30
- Last updated
- 2023-11-18
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00871936. Inclusion in this directory is not an endorsement.